BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Neurology

Actinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design

Changes to the XanaMIA protocol reduce cost by AUD 30 million over the next two years and speed time to initial results while preserving the 36-week design...

September 27, 2023 | News

Ascletis Completes Enrollment for Glioblastoma Treatment Trial

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the completion of enrollment of 120 patients in the Phase III registration clinical trial of ...

September 27, 2023 | News

Cerecin strengthens position in neurometabolism with addition to pipeline

Cerecin completes in-licensing of an investigational radiolabelled tracer 18FBHB, CER-022, for development and use in positron emission tomography (...

September 20, 2023 | News

Oscotec/ADEL Receives FDA Clearance for Alzheimer's Treatment IND Application (ADEL-Y01)

Oscotec and ADEL are jointly developing a novel disease-modifying immunotherapy agent (ADEL-Y01) targeting tau protein accumulation in the AD brain. ADEL-Y...

September 15, 2023 | News

IBT and ATLATL Join Forces to Tackle Challenges in Brain Health

Starting out of China, IBT Global is a rising player in Digital Therapeutics (DTx) with an experienced cross-functional team operating at the intersection ...

September 05, 2023 | News

Salvia BioElectronics Treats First Patient with Neuromodulation for Severe Migraine in Australia

The first patient, a 29-year-old woman from Australia who has suffered from debilitating headaches since the age of 14, experienced immediate and...

August 24, 2023 | News

Sunbird Bio Joins Glympse Bio to Advance Protein-Based Diagnostics

Combined company will operate as Sunbird Bio and focus on advancing clinical-stage platforms with demonstrated potential to enhance patient care in A...

August 14, 2023 | News

Neurophth Raises Almost $95M for Gene Therapy Trials in Series C+ Funding

Additionally, several prominent investment firms participated, including CMG-SDIC Capital, Silicon Paradise Asset Management and Yangtze River Industry Fun...

August 14, 2023 | News

First Patient Dosed in TLX101 Brain Cancer Study for Newly Diagnosed Glioblastoma

IPAX-2 (ClinicalTrials.gov Identifier: NCT05450744) is a Phase I dose escalation study to confirm safety profile of TLX101 in combination with externa...

August 08, 2023 | News

World's First Report: Plasmacluster Technology's Potential to Induce Brain Activation

Sharp Corporation conducted collaborative research on its Plasmacluster technology, with Dr. Goichi Hagiwara, Associate Professor, Faculty of Human Sc...

July 27, 2023 | News

Project Matty to Revolutionize Care for Children with Autism and ADHD Through AI

The co-founders' personal journeys fuel their resolve to bridge the gap in traditional treatments. Born out of one mother's determination to help her ADHD-...

July 25, 2023 | News

CRISPR Gene Editing Opens New Treatment Avenues for Alzheimer's

Two new CRISPR-based strategies offer hope for next-generation Alzheimer's treatments. One seeks to dampen the impact of the most common Alzheimer's ris...

July 17, 2023 | News

Zymedi Collaborates with National Heart, Lung, and Blood Institute to Develop ZMA001 mAb for PAH Treatment

The CRADA between Zymedi and the NHLBI will enable the organizations to collaborate together to advance the development of ZMA001. Zymedi will work...

July 03, 2023 | News

Promising Clinical Trial Data for Migraine Treatment: CER-0001, a Ketogenic Investigational Agent

A poster showcasing data from the RELIEF study of CER-0001 (tricaprilin), being investigated for the preventive treatment of migraine, was presented at t...

July 03, 2023 | News

Stay Connected